ADVERTISEMENT

Lasa Supergenerics Says Will Maintain Margins Unless Oil Plays Spoilsport

In an interview to BloombergQuint, Omkar Herlekar of Lasa Supergenerics talked about the road ahead for the company.

A worker tests a liquid chemical inside a laboratory of a research and development facility in Cambridge, U.S. (Photographer: Scott Eisen/Bloomberg)
A worker tests a liquid chemical inside a laboratory of a research and development facility in Cambridge, U.S. (Photographer: Scott Eisen/Bloomberg)

Lasa Supergenerics Ltd., a Mumbai-based veterinary active pharmaceutical intermediate maker, expects to maintain margin at 36-40 percent of gross profit level unless oil prices play further spoilsport.

In an interview to BloombergQuint, Omkar Herlekar, managing director at Lasa Supergenerics talked about the road ahead for the company. “We will be sticking to the veterinary space – feed and medicine – for our future growth plan.”

Watch the full conversation here: